


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1- (Original) Compound of the formula I:



in which

A and B independently represent an optionally substituted phenyl nucleus; or an optionally substituted pyridyl nucleus;

T represents an optionally substituted, saturated and/or unsaturated aromatic carbocyclic nucleus; an optionally substituted, saturated and/or unsaturated aromatic heterocyclic nucleus; or

T represents a saturated and/or unsaturated aromatic carbocyclic nucleus which is fused to the nucleus A, is optionally substituted and is linked to two adjacent carbon atoms belonging to the nucleus A;

R represents a hydrogen atom; an optionally substituted saturated aliphatic hydrocarbon-based group; or an optionally substituted, saturated or unsaturated aromatic carbocyclic group;

n represents an integer chosen between 1, 2, 3, 4 and 5;

the radicals X<sub>i</sub> and Y<sub>i</sub> are independently chosen from a hydrogen atom; a halogen atom; an optionally substituted, saturated and/or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated or unsaturated aromatic carbocyclic nucleus; a-u<sup>1</sup>-COOL group, in which u<sup>1</sup> represents a bond or an alkylene group and L is an optionally substituted saturated aliphatic hydrocarbon-based group or an optionally substituted, saturated and/or unsaturated aromatic carbocyclic group; -u<sup>2</sup>-SiR<sup>1</sup>R<sup>2</sup>R<sup>3</sup>, in which u<sup>2</sup> represents a bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to Si and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently represent an optionally substituted saturated aliphatic hydrocarbon-based group; -u<sup>3</sup>-OW, in which u<sup>3</sup> represents a bond or an alkylene group and W may represent a hydrogen atom or is as defined above for L; u<sup>4</sup>-CO-G, in which u<sup>4</sup> represents a

bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to the carbonyl group and G is as defined above for L; -u<sup>5</sup>-CO-NH-J, in which u<sup>5</sup> represents a bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to the carbonyl group and J is as defined above for L; or a radical Xi and a radical Yi both attached to the same carbon atom, together with this carbon atom, represent an optionally substituted saturated carbocyclic nucleus;

and the pharmaceutically usable derivatives, solvates and stereoisomers thereof comprising a mixture thereof in all proportions.

2- (Original) Compound according to Claim 1, in which A and B represent optionally substituted phenyl.

3- (Original) Compound according to Claim 1, in which B represents optionally substituted phenyl; and A represents optionally substituted pyridyl.

4- (Currently Amended) Compound according to claim 1 any one of the preceding claims, characterised in that T represents an optionally substituted monocyclic or bicyclic aryl nucleus; a saturated or unsaturated, monocyclic or bicyclic aromatic heterocyclic nucleus containing 1 to 3 heteroatoms chosen from N, O and S, the said nucleus being optionally substituted by one or more radicals chosen from oxo, a halogen atom, alkyl which is optionally halogenated and/or optionally interrupted by one or more oxygen or sulfur atoms; -alk<sup>1</sup>-O-CO-R<sup>4</sup>, in which alk<sup>1</sup> is an alkylene radical and R<sup>4</sup> represents alkyl or alkylamino; -alk<sup>2</sup>-CO-O-R<sup>5</sup>, in which alk<sup>2</sup> is an alkylene radical and R<sup>5</sup> is as defined above for R<sup>4</sup>; -CO-R<sup>6</sup>, in which R<sup>6</sup> is as defined above for R<sup>4</sup>; hydroxyalkyl; -alk<sup>3</sup>-TT-Q, in which alk<sup>3</sup> represents alkylene, TT represents O or NH, and Q represents an optionally substituted arylalkyl nucleus; optionally substituted heteroarylalkyl; -CO-K, in which K represents alkyl or alkoxy; or -SO<sub>2</sub>-K in which K is as defined above; -alk<sup>4</sup>-O-CO-NH-alk<sup>5</sup>, in which -alk<sup>4</sup> and alk<sup>5</sup> independently represent alkylene; aminoalkyl; hydroxyalkyl, heteroarylalkyl, preferably imidazolylalkyl; and alkenyl.

5- (Currently Amended) Compound according to claim 1 any one of the preceding claims, characterised in that R is chosen from H and alkyl.

6- (Currently Amended) Compound according to claim 1 any one of the preceding claims, characterised in that n represents 1, 2 or 3.

7- (Currently Amended) Compound according to claim 1 ~~any one of the preceding claims~~, characterised in that the radicals Xi and Yi are independently chosen from a hydrogen atom; a halogen atom; an alkyl group which is optionally interrupted by one or more oxygen or sulfur atoms; a hydroxyalkyl group; -COOL, in which L is as defined in Claim 1; -alk<sup>3</sup>-SiR<sup>1</sup>R<sup>2</sup>R<sup>3</sup>, in which alk<sup>3</sup> represents alkylene and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1; -alk<sup>4</sup>-O-CO-alk<sup>5</sup>, in which alk<sup>4</sup> and alk<sup>5</sup> independently represent alkyl; -alk<sup>6</sup>-O-CO-NH-alk<sup>7</sup>, in which alk<sup>6</sup> and alk<sup>7</sup> independently represent alkyl.

8- (Currently Amended) Compound according to claim 1 ~~any one of the preceding claims~~, characterised in that A represents phenyl which is optionally substituted by halogen, alkyl or alkoxy, and in that B represents phenyl which is optionally substituted by halogen, alkyl or alkoxy.

9- (Currently Amended) Compound according to claim 1 ~~any one of the preceding claims~~, characterised in that A represents pyridyl; B represents phenyl; n represents 1, 2 or 3; R represents H; and the radicals Xi and Yi represent a hydrogen atom or a fluorine atom.

10- (Currently Amended) Compound according to claim 1 ~~any one of the preceding claims~~, characterised in that the radicals Xi and Yi attached to the same carbon atom are identical and both represent a hydrogen atom or both represent a fluorine atom.

11- (Currently Amended) Compound according to claim 1 ~~any one of the preceding claims~~, characterised in that T represents a nucleus chosen from phenyl, pyrrolyl, phthalimidyl and succinimidyl, the said nucleus being optionally substituted by one or more radicals chosen from:

- alkyl which is optionally halogenated and/or optionally interrupted by one or more oxygen or sulfur atoms;

- alk<sup>1</sup>-O-CO-R<sup>4</sup>, in which alk<sup>1</sup> is an alkylene radical and R<sup>4</sup> represents alkyl or alkylamino;

- alk<sup>2</sup>-CO-O-R<sup>5</sup>, in which alk<sup>2</sup> is an alkylene radical and R<sup>5</sup> is as defined above for R<sup>4</sup>;

- CO-R<sup>6</sup>, in which R<sup>6</sup> is as defined above for R<sup>4</sup>;

- hydroxyalkyl;

- heteroarylalkyl, preferably imidazolylalkyl; and

-alkenyl.


12- (Original) Compound of the formula I according to Claim 1, chosen from:

- 5-(4'-trifluoromethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-isopropylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-methoxybiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-trifluoromethoxybiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-isopropylbiphen-2-ylcarbonylamino)benzo[1,3]dioxole;
- 5-(4'-ethyl-3-methylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-ethylaminocarbonyloxyethylbiphen-2-ylcarbonylamino)-2,2-difluoro-  
benzo[1,3]dioxole;
- 5-(4'-trifluoromethoxy-3-methylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-methoxycarbonylethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 4'-isopropylbiphenyl-2-carboxylic acid (3-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-  
yl)amide;
- 7-[(4'-isopropylbiphenyl-2-carbonyl)amino]-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl  
ethylcarbamate;
- 4'-ethylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 4'-trifluoromethoxybiphenyl-2-carboxylic acid benzo[1,3]dioxol-5-ylamide;
- 4'-(2-hydroxyethyl)biphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 4'-isobutylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 4'-(2-methylpropenyl)biphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 6-chloro-4'-isopropylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 6-chloro-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-  
yl)amide;
- 4'-(2-benzyloxyethyl)-6-methylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-  
yl)amide;
- 6-methoxy-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-  
yl)amide;
- 6-methyl-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2-methoxymethyl-2,3-  
dihydrobenzo[1,4]dioxin-6-yl)amide;
- 6-[(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)amino]-2,3-dihydrobenzo[1,4]dioxin-2-  
ylmethyl ethylcarbamate;


- 2-[6'-(2,2-difluorobenzo[1,3]dioxol-5-ylcarbamoyl)-2'-methylbiphenyl-4-yl]ethyl ethylcarbamate;

- 4'-ethylbiphenyl-2-carboxylic acid benzo[1,3]dioxol-5-ylamide.

13- (Currently Amended) Process for the preparation of compounds of the formula I as defined in claim 1 ~~any one of Claims 1 to 12~~, characterised in that a carboxylic acid of the formula II:



in which A and T are as defined in claim 1 ~~any one of Claims 1 to 12~~, optionally in activated form, is reacted with an amine of the formula III:



in which R, Xi, Yi, n and B are as defined in claim 1 ~~any one of Claims 1 to 12~~.

14- (Original) Process for the preparation of compounds of the formula I in which R represents an optionally substituted saturated aliphatic hydrocarbon-based group; or an optionally substituted, saturated or unsaturated aromatic carbocyclic group, the said process comprising the reaction of the amino function attached to the nuclei A and B of the corresponding compound of the formula I in which R 5- represents a hydrogen atom, with a suitable electrophilic site.


Compound of the formula XXI a



in which ( )— denotes the possible substituent(s) on the phenyl group to which ( ) is attached, which are chosen from halogen, alkyl and alkoxy.

Compound according to Claim 15, for which ( ) denotes methyl.


Compound of the formula XIVa:



in which ( )— denotes the possible substituent(s) on the phenyl group to which ( ) is attached, which are chosen from halogen, alkyl and alkoxy.

18- (Original) Compound according to Claim 17 of the formula XIVa, for which ( ) denotes a hydrogen atom or a methyl group.

19- (Original) Compound of the formula IIb:




in which

P is chosen from  $-\text{OCF}_3$  provided that ( ) does not represent hydrogen;  
 $-\text{CO-CH}(\text{CH}_3)_2$ ;  $-(\text{CH}_2)_2\text{-O-CO-CH}_3$ ;  $-(\text{CH}_2)_2\text{-CO-O-CH}_3$ ; and  $-(\text{CH}_2)_2\text{-O-CO-NH-CH}_2\text{-CH}_3$ ;  
( )— denotes the possible substituent(s) on the phenyl group to which ( ) is attached, which are chosen from hydrogen, halogen, such as chlorine, alkyl, such as methyl and alkoxy, such as methoxy.

20- (Original) Compound according to Claim 19 of the formula IIb, chosen from:  
6-methyl-4'-trifluoromethoxybiphenyl-2-carboxylic acid;  
6-methoxy-4'-trifluoromethoxybiphenyl-2-carboxylic acid;  
6-chloro-4'-trifluoromethoxybiphenyl-2-carboxylic acid;  
4'-isobutyrylbiphenyl-2-carboxylic acid;

4'-(2-acetoxyethyl)biphenyl-2-carboxylic acid;  
 4'-(2-methoxycarbonylethyl)biphenyl-2-carboxylic acid;  
 4'-(2-ethylcarbamoyloxyethyl)biphenyl-2-carboxylic acid;  
 4'-(2-ethylcarbamoyloxyethyl)-6-methylbiphenyl-2-carboxylic acid.


21- (Original) Compound of the formula IIId:



in which r represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, preferably methyl, and NH<sub>2</sub> is located in position 6 or 7, with the exclusion of 2-ethoxymethyl-2,3-dihydro-benzo[1,4]dioxin-7-ylamine.

22- (Original) Compound according to Claim 21 of the formula IIIc, chosen from:  
 3-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-ylamine; and  
 2-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-ylamine.


23- (Original) Compound of the formula XIa:



in which r represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, preferably methyl, and NO<sub>2</sub> is located in position 6 or 7, with the exclusion of 2-ethoxymethyl-7-nitro-2,3-dihydro-benzo[1,4]dioxine.

24- (Original) Compound of the formula XIa according to Claim 23, chosen from:  
 2-methoxymethyl-7-nitro-2,3-dihydrobenzo[1,4]dioxine;  
 2-methoxymethyl-6-nitro-2,3-dihydrobenzo[1,4]dioxine.


25- (Original) Compound of the formula IIIe:



in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently represent (C<sub>1</sub>-C<sub>6</sub>)alkyl and -NH<sub>2</sub> is located in position 6 or 7.

26- (Original) Compound of the formula IIIb according to Claim 25, chosen from:  
3-(*tert*-butyldimethylsilyloxyethyl)-2,3-dihydrobenzo[1,4]dioxin-6-ylamine, and  
2-(*tert*-butyldimethylsilyloxyethyl)-2,3-dihydrobenzo[1,4]dioxin-6-ylamine.

27- (Original) Compound of the formula IVa:



in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently represent (C<sub>1</sub>-C<sub>6</sub>)alkyl; and NO<sub>2</sub> is located in position 6 or 7.

28- (Original) Compound of the formula IVa according to Claim 27, chosen from:  
*tert*-butyldimethyl(7-nitro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethoxy)silane;  
*tert*-butyldimethyl(6-nitro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethoxy)silane.

29- (Currently Amended) Pharmaceutical composition comprising one or more compounds of the formula I as defined in claim 1 ~~any one of Claims 1 to 12~~, in combination with one or more excipients.

30- (Currently Amended) Use of a compound of the formula I according to claim 1 ~~any one of Claims 1 to 12~~, for the preparation of a pharmaceutical composition for inhibiting microsomal triglyceride transfer protein (MTP).

31- (Original) Use according to Claim 29, characterised in that the said pharmaceutical composition is intended for the treatment of hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia, pancreatitis, hyperglycaemia, obesity, atherosclerosis and diabetes-related dyslipidaemia.